Faeth Therapeutics, Inc.
FTH- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001829802
In the last 90 days, Faeth Therapeutics, Inc. insiders filed 1 open-market purchase and 0 sales; 45 institutions reported holding it in 13F filings for Q2 2026, worth $333.8M in total; no superinvestor holds it.
13F holders, Q2 2025
Institutional positions in Faeth Therapeutics, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 10
- −10 vs. Q1 2025
- Shares held
- 69.9K
- −1.86M (−96.4%) vs. Q1 2025
- Total value
- $600.0K
- −$160.2K (−21.1%) vs. Q1 2025
- New holders
- 0
- 2 more added
- Sold out
- 10
- 8 more reduced
Compare with Q1 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting FTH on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 45 | $333.8M |
| Q1 2026 | 30 | $72.2M |
| Q4 2025 | 10 | $514.8K |
| Q3 2025 | 9 | $466.5K |
| Q2 2025 | 10 | $600.0K |
| Q1 2025 | 20 | $760.2K |
| Q4 2024 | 24 | $1.16M |
| Q3 2024 | 19 | $1.32M |
| Q2 2024 | 24 | $1.31M |
| Q1 2024 | 25 | $2.45M |
| Q4 2023 | 24 | $2.05M |
| Q3 2023 | 23 | $2.38M |
| Q2 2023 | 26 | $3.58M |
| Q1 2023 | 27 | $4.71M |
| Q4 2022 | 28 | $3.93M |
| Q3 2022 | 31 | $4.47M |
| Q2 2022 | 40 | $7.06M |
| Q1 2022 | 43 | $8.21M |
| Q4 2021 | 38 | $19.7M |
| Q3 2021 | 42 | $37.1M |
| Q2 2021 | 34 | $22.7M |
| Q1 2021 | 40 | $45.8M |
Institutions, Q2 2025
Shares, value and share of portfolio for each institution holding Faeth Therapeutics, Inc.; share changes are against Q1 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Vanguard Group Inc | 29,090 | $249.6K | 0.00% | −556,486−95.0% | Reduced |
| Ikarian Capital, LLC | 22,497 | $193.0K | 0.06% | −427,466−95.0% | Reduced |
| Catalio Capital Management, LP | 14,718 | $126.3K | 0.03% | −279,656−95.0% | Reduced |
| UBS Group AG | 2,140 | $18.4K | 0.00% | −40,401−95.0% | Reduced |
| Raymond James Financial Inc | 700 | $6.01K | 0.00% | −13,300−95.0% | Reduced |
| Bank of America Corp | 583 | $5.00K | 0.00% | +441+310.6% | Added |
| SBI Securities Co., Ltd. | 149 | $1.28K | 0.00% | +57+62.0% | Added |
| JPMorgan Chase & Co | 32 | $275 | 0.00% | −670−95.4% | Reduced |
| Morgan Stanley | 10 | $86 | 0.00% | −9,209−99.9% | Reduced |
| BNP Paribas Arbitrage, SA | 9 | $77 | 0.00% | −151−94.4% | Reduced |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −177,300−100.0% | Sold out |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −150,709−100.0% | Sold out |
| Boothbay Fund Management, LLC | 0 | $0 | 0.00% | −108,658−100.0% | Sold out |
| Northern Trust Corp | 0 | $0 | 0.00% | −25,983−100.0% | Sold out |
| State Street Corp | 0 | $0 | 0.00% | −25,774−100.0% | Sold out |
| Cresset Asset Management, LLC | 0 | $0 | 0.00% | −19,671−100.0% | Sold out |
| NWF Advisory Services Inc. | 0 | $0 | 0.00% | −16,514−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −5,404−100.0% | Sold out |
| Barclays PLC | 0 | $0 | 0.00% | −2,558−100.0% | Sold out |
| Citigroup Inc | 0 | $0 | 0.00% | −124−100.0% | Sold out |